Why the study?
Does a higher modified CHADS2 score predict an increased risk of thromboembolic events in patients with nonvalvular atrial fibrillation?
Does a higher modified CHADS2 score predict an increased risk of thromboembolic events in patients with nonvalvular atrial fibrillation?
Accumulation of risk factors, quantified by a modified CHADS2 score, significantly increases the risk of thromboembolic events in patients with nonvalvular atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
Higher modified CHADS2 scores associate with greater thromboembolic risk in nonvalvular AF irrespective of warfarin; supports stratification but leaves open prospective outcome trials.
Inoue et al. (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: